Clinical Trials Logo

Filter by:
NCT ID: NCT01800747 Completed - Acute Otitis Media Clinical Trials

Clinical Trial for the Assessment of Delayed Antibiotic Treatment in Pediatric (DAP-Pediatrics)

DAP
Start date: June 2012
Phase: Phase 4
Study type: Interventional

The general hypothesis is that delayed antibiotic treatment strategy present similar effectiveness, when compared with non-prescription of antibiotics or the prescription of antibiotics, in the non-complicated acute respiratory tract infections in pediatric patients.

NCT ID: NCT01800474 Completed - Clinical trials for Health Knowledge, Attitudes, Practice

A Non-interventional Study to Evaluate the Use of Pliaglis in Daily Practice

Start date: February 2013
Phase:
Study type: Observational

A multe-center, non-interventional study in Europe to evaluate Pliaglis in daily practice

NCT ID: NCT01800279 Completed - Clinical trials for Temporomandibular Joint Dysfunction Syndrome

Physiotherapy and Deontology in the Temporomandibular Joint Dysfunction in Patients With Fibromyalgia Syndrome.

Start date: March 2013
Phase: N/A
Study type: Interventional

The purpose of this study is to determine whether kinesitherapy techniques and a myofascial therapy protocol are effective in the treatment of temporomandibular joint dysfunction in patients with fibromyalgia syndrome.

NCT ID: NCT01800058 Completed - Clinical trials for Patients With High-risk Prostate Cancer

Circulating Tumor Cells in High-Risk Prostate Cancer Treated With High-dose Radiotherapy and Hormone Therapy

Start date: January 2014
Phase:
Study type: Observational

The detection and quantification of Circulating tumor cells CTCs in peripheral blood of patients with prostate adenocarcinoma may be useful at least for: Getting a correct stratification of patients with high-risk prostate cancer (PCa). Set the prognosis at baseline. Evaluate the response to different treatments (predictive value and monitoring). Establish individualized therapies.

NCT ID: NCT01799720 Completed - Overweight Clinical Trials

Oxidized Omega-3 Supplements With Different Oxidation

GPTPASPAD
Start date: October 2010
Phase: N/A
Study type: Interventional

The oxidation level of unsaturated fatty acid supplements commercialized in capsules could be a serious problem for manufacturers and a risk to consumers; health by ingesting substances whose effects are not desired. Therefore, the main objective of this paper is to analyze the effect of dietary supplements Omega-3 with different levels of oxidation in the lipid profile of women who consume these supplements. For this purpose the investigators have designed a single-blind, parallel-groups, randomized controlled trial. Finally, 52 women between 25 and 75 years old were randomly distributed into three groups: (1) took 2 capsules/day of one of the less oxidized oil (containing 300 mg EPA + DHA) and diet, (2) took 2 capsules/day of one of the most oxidized oil (containing 300 mg EPA + DHA) and diet and (3) no capsules, only received the diet. There was a 30 days follow-up . All groups followed a low cholesterol diet. Circulating glucose, total cholesterol, triglycerides and glutamic pyruvic transaminase were determined at the beginning and end of a 30 day period.

NCT ID: NCT01799694 Completed - Clinical trials for Urinary Incontinence

Stem Cells Treatment for the Local Urinary Incontinence After a Radical Prostate Cancer Surgery (HULPURO)

FLPURO
Start date: July 2011
Phase: Phase 2
Study type: Interventional

The purpose of this study is to evaluate the feasibility and security of the autologous e-ASC for the urinary incontinence after a radical prostate cancer surgery

NCT ID: NCT01799564 Completed - Clinical trials for Age-related Macular Degeneration

Micropulse Laser for Geographic Atrophy

MPL4DRY
Start date: August 2012
Phase: N/A
Study type: Interventional

Geographic atrophy (GA) causes the loss of the retinal pigment epithelium (RPE) cells in broad areas of the retina. The application of subthreshold micropulse laser spots in healthy RPE in the vicinity of the area of GA may restore the imbalance in survival factors caused by the disease (ie, the laser may decrease vascular endothelial growth factor and RPE-derived transforming growth factor beta, upregulation of pigment epithelium-derived factor). This may slow or even stop the enlargement of atrophy secondary to GA, and therefore, avoid further vision loss.

NCT ID: NCT01799421 Completed - Clinical trials for Non-hematologic Cancer

Risk Assessment of Febrile Neutropenia and Grade 3-4 Neutropenia in Patients With Non-hematological Cancer Treated With Conventional Chemotherapy

NEURISK
Start date: October 2011
Phase: N/A
Study type: Observational

The purpose of this study is to identify prognostic factors and to develop predictive models of risk of febrile neutropenia and neutropenia grade 3/4 in patients with solid tumors receiving chemotherapy with schemas that have an inherent risk of febrile neutropenia of 10-20%.

NCT ID: NCT01799148 Completed - Clinical trials for Patients With Acute Coronary Syndrome

Air Pollution, Inflammation and Acute Coronary Syndrome

AIRACOS
Start date: November 2011
Phase: N/A
Study type: Observational [Patient Registry]

The objectives of this study are: 1) To determine whether patients with acute coronary syndrome, the level of environmental exposure to particulate air pollutants in the week prior to admission, are related to concentrations of inflammatory molecules and oxidative stress. 2) To investigate whether the level of environmental exposure is an independent prognostic factor in terms of overall and cardiovascular mortality, myocardial infarction or unstable angina at 30 days, 6 and 12 months.

NCT ID: NCT01798706 Completed - Type 2 Diabetes Clinical Trials

Efficacy and Safety of Lixisenatide Versus Placebo on Top of Basal Insulin and/or Oral Antidiabetic Treatment in Older Type 2 Diabetic Patients

GetGoal-O
Start date: June 2013
Phase: Phase 3
Study type: Interventional

Primary objective: - To evaluate the effect of lixisenatide versus placebo over a period of 24 weeks on glycemic control, as evaluated by HbA1c reduction, in older type 2 diabetes patients (T2DM) who are inadequately controlled with their current anti-diabetic treatment regimen. Main secondary objective: - To assess the safety and tolerability of lixisenatide compared to placebo in older T2DM patients (including occurrence of documented (Plasma Glucose PG < 60 mg/dL) symptomatic hypoglycemia and gastrointestinal side effects). Other secondary objectives: - To assess the effect of lixisenatide compared to placebo after 24-week treatment on: - Fasting plasma glucose (FPG) - During liquid standardized breakfast meal challenge test : 2 hour- PPG and Plasma Glucose Excursion - 7-point Self-monitored plasma glucose (SMPG) profile - Body weight - Change in total daily dose of basal insulin (if taken) - Percentage of patients requiring rescue therapy - Safety and tolerability - To assess lixisenatide pharmacokinetic profile - To assess anti-lixisenatide antibody development.